The association between different predictive biomarkers and mortality of COVID-19

Narges Ansari; Mina Jahangiri; Kimia Shirbandi; Mina Ebrahimi; Fakher Rahim

doi:10.1186/s42269-022-00844-7

The association between different predictive biomarkers and mortality of COVID-19

Bull Natl Res Cent. 2022;46(1):158. doi: 10.1186/s42269-022-00844-7. Epub 2022 May 31.

Authors

Narges Ansari¹, Mina Jahangiri², Kimia Shirbandi³, Mina Ebrahimi^{4

5}, Fakher Rahim⁴

Affiliations

¹ Department of Internal Medicine, Isfahan Bone Metabolic Disorders Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
² Department of Biostatistics and Epidemiology, Faculty of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
³ Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
⁴ Thalassemia and Hemoglobinopathy Research Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
⁵ Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Background: Immunocompromised individuals are expected to be more prone to severe diseases and, subsequently, death. Genetic disorders and polymorphisms in genes involved in the immune system, such as human leukocyte antigen (HLA), inflammatory cytokines, and killer-cell immunoglobulin-like receptors, can be involved in the immune system's response to various pathogens. In the current survey, the data were received from the world health organization, collected around the world.

Results: Spearman's coefficient correlation test for evaluating the relationship between the Daily Death Rates (DDR) and immunological variables showed a statistically significant correlation between the DDR and all immunological variables except TNFa857T, TNFa863A IL2330G, and IL2166T (P < 0.001). Also, there was a statistically significant correlation between the DDR and some HLA markers.

Conclusion: This meta-analysis study shows that predictive biomarkers and mortality of COVID-19 are associated with HLA markers. However, these results should be confirmed in a more structured agreement. It is worth noting that the design of new studies should consider potential diseases with poor prognoses because they are related to these immune genetic markers.

Supplementary information: The online version contains supplementary material available at 10.1186/s42269-022-00844-7.

Keywords: Biomarker; COVID-19; HLA; Polymorphism.